<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230713058769N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-07-29</date_registration>
      <primary_sponsor>Arak University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of ephedrine, ketamine, ondansetron and atropine drugs to prevent nausea and vomiting during and after surgery in patients under spinal anesthesia</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of ephedrine, ketamine, ondansetron and atropine drugs to prevent nausea and vomiting during and after surgery in patients under spinal anesthesia for lower limb fracture repair</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>128</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/71298</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: Patients will be divided into 4 groups based on the balanced block randomization pattern and the size of the blocks will be 8. The randomization is done by the consultant professor using the online program at https://www.sealedenvelope.com/. Hiding the random chain is done by the method of opaque envelopes, Blinding description: The study will be designed in a double-blind manner. The method of blinding is that the anesthesiologist prepares the drugs and the anesthetist performs the spinal anesthesia. A student who is responsible for recording information in certain time intervals. Also, the groups are sent to the statistician using coding, and the analyst does not know about the grouping.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Postoperative nausea and vomiting.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Before spinal anesthesia, they will receive 5 mg of ephedrine (Sterop belgium pharmaceutical company). In order to equalize the volume of the intervention drug in all groups, after calculating the desired dose, it will be brought to 5 ml with distilled water. And it is administered intravenously. Intervention 2: Intervention group 2: Before spinal anesthesia, they will receive 100 micrograms of atropine (Caspin Pharmaceutical Company, Rasht Supply - Iran). In order to equalize the volume of the intervention drug in all groups, after calculating the desired dose, it will be brought to 5 ml with distilled water. And it is administered intravenously. Intervention 3: Intervention group 3: Before spinal anesthesia, they will receive 8 mg of ondansetron (Alborz Daru Pharmaceutical Company). In order to equalize the volume of the intervention drug in all groups, after calculating the desired dose, it will be brought to 5 ml with distilled water. And it is administered intravenously. Intervention 4: Intervention group 4: Before the spinal anesthesia, they will receive 0.3 mg per kg of ketamine (Exir pharmaceutical company - Iran). In order to equalize the volume of the intervention drug in all groups, after calculating the desired dose, it will be brought to 5 ml with distilled water. And it is administered intravenously.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Hesamoddin Modir</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Valiasr Hospital, Valiasr Square</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3814957558</zip>
        <telephone>+98 86 3222 2003</telephone>
        <email>modir.he@gmail.com</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Hesamoddin Modir</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Valiasr Hospital, Valiasr Square</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3814957558</zip>
        <telephone>+98 86 3222 2003</telephone>
        <email>modir.he@gmail.com</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age 18-75 years old
Both genders
ASA class 1 and 2
Lower limb fracture repair surgery under spinal anesthesia
Consent to participate in the study</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>75 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of drug addiction
History of seasonal allergies and allergies to any of the drugs used in this study
Presence of neuromuscular diseases
Presence of cardiomyopathy
Presence of coagulopathy
Presence of an underlying disease</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>R11</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Nausea and vomiting</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Before spinal anesthesia, they will receive 5 mg of ephedrine (Sterop belgium pharmaceutical company). In order to equalize the volume of the intervention drug in all groups, after calculating the desired dose, it will be brought to 5 ml with distilled water. And it is administered intravenously.</i_keyword>
      <i_keyword>Intervention group 2: Before spinal anesthesia, they will receive 100 micrograms of atropine (Caspin Pharmaceutical Company, Rasht Supply - Iran). In order to equalize the volume of the intervention drug in all groups, after calculating the desired dose, it will be brought to 5 ml with distilled water. And it is administered intravenously.</i_keyword>
      <i_keyword>Intervention group 3: Before spinal anesthesia, they will receive 8 mg of ondansetron (Alborz Daru Pharmaceutical Company). In order to equalize the volume of the intervention drug in all groups, after calculating the desired dose, it will be brought to 5 ml with distilled water. And it is administered intravenously.</i_keyword>
      <i_keyword>Intervention group 4: Before the spinal anesthesia, they will receive 0.3 mg per kg of ketamine (Exir pharmaceutical company - Iran). In order to equalize the volume of the intervention drug in all groups, after calculating the desired dose, it will be brought to 5 ml with distilled water. And it is administered intravenously.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Vomiting score according to the vomiting score table. Timepoint: In recovery, 2, 4, 6, 12 and 24 hours after the operation. Method of measurement: Physical examination.</prim_outcome>
      <prim_outcome>Number of times nausea occurs. Timepoint: In recovery, 2, 4, 6, 12 and 24 hours after the operation. Method of measurement: Physical examination.</prim_outcome>
      <prim_outcome>Severity of nausea according to visual analogue scale. Timepoint: In recovery, 2, 4, 6, 12 and 24 hours after the operation. Method of measurement: Visual Analogue Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>The degree of sedation according to the RAMSAY SCORE. Timepoint: In recovery and 1, 2 and 4 hours after the operation. Method of measurement: RAMSAY SCORE.</sec_outcome>
      <sec_outcome>Dosage of Metoclopramide. Timepoint: Within 24 hours after the operation. Method of measurement: Patient file.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice chancellor of Research of Arak University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-06-27</approval_date>
        <contact_name>Ethics Committee of Arak University of Medical Sciences</contact_name>
        <contact_address>Vice chancellor of Research, Prophet Azam University Complex, Arak University of Medical Sciences Arak Markazi Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
